Using CRISPR gene editing to switch off HIV by targeting a protein HIV needs
A CRISP(e)R way to silence HIV
This project uses CRISPR gene editing to turn off HIV in people living with HIV who still have hidden viral reservoirs despite treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Florida International University NIH-funded |
| Lab location | 1 site (Miami, United States) |
| Project ID | NIH-11237557 on NIH RePORTER |
What this research studies
This research aims to block a human protein called CyclinT1 that HIV uses to turn on its genes, using CRISPR-based gene editing. The team will work in laboratory models and human-derived samples to test whether targeting this host factor can stop HIV transcription without harming normal cell functions. The approach focuses on preventing the virus from reactivating from hidden reservoirs that remain despite antiretroviral therapy. The researchers are addressing known challenges such as viral escape, off-target effects, and delivery to infected cells.
Who could benefit from this research
Good fit: Ideal candidates would be people living with HIV who are stable on antiretroviral therapy but still carry latent HIV reservoirs and are open to gene-based intervention research.
Not a fit: People without HIV or those who cannot or choose not to undergo experimental gene therapies would not directly benefit from this project.
Why it matters
Potential benefit: If successful, this approach could silence HIV in reservoir cells and move people closer to long-term remission or a cure.
How similar studies have performed: Prior lab and animal work has shown CRISPR can excise or silence HIV, but delivery, viral escape, and safety remain unresolved obstacles.
Where this research is happening
Miami, United States
- Florida International University — Miami, United States (Active)
Researchers
- Principal investigator: Unwalla, Hoshang Jehangir — Florida International University
- Study coordinator: Unwalla, Hoshang Jehangir
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.